Variable | BSLE group (n = 12) | Single SLE group (n = 48) | P value |
---|---|---|---|
Age (years, mean ± SD) | 25.9 ± 13.3 | 27.3 ± 14.4 | 0.766 |
Gender (F/M) | 2/10 | 4/44 | 0.389 |
Disease duration (months, mean ± SD) | 26.5 ± 32.9 | 46.0 ± 51.2 | 0.215 |
Arthritis (n, %) | 6 (50.0) | 22 (45.8) | 0.796 |
Renal involvement (n, %) | 11 (91.7) | 25 (52.1) | 0.012* |
Nephrotic syndrome (n, %) | 4 (33.3) | 6 (12.5) | 0.083 |
Proteinuria (n, %) | 10 (83.3) | 23 (47.9) | 0.027* |
Hematuria (n, %) | 9 (75.0) | 15 (31.3) | 0.006* |
Renal insufficiency (n, %) | 4 (33.3) | 6 (12.5) | 0.083 |
Hemocytopenia (n, %) | 10 (83.3) | 19 (39.6) | 0.007* |
Hemolytic anemia (n, %) | 4 (33.3) | 0 (0.0) | 0.000* |
Leukopenia (n, %) | 8 (66.7) | 12 (25.0) | 0.006* |
Thrombocytopenia (n, %) | 2 (16.7) | 12 (25.0) | 0.542 |
Myositis (n, %) | 0 (0) | 3 (6.3) | 0.374 |
Neurological involvement (n, %) | 3 (25.0) | 9 (18.8) | 0.628 |
Cardiac damage (n, %) | 2 (16.7) | 17 (35.4) | 0.212 |
Gastrointestinal involvement (n, %) | 1 (8.3) | 8 (25.0) | 0.449 |
Anti-dsDNA antibody (n, %) | 8 (66.7) | 23 (47.9) | 0.245 |
Anti-Sm antibody (n, %) | 2 (16.7) | 7 (14.6) | 0.857 |
Anti-RNP antibody (n, %) | 2 (25.0) | 14 (29.2) | 0.774 |
Anti-rRNP antibody (n, %) | 4 (33.3) | 6 (12.5) | 0.083 |
Anti-SSA antibody (n, %) | 6 (50.0) | 16 (33.3) | 0.284 |
Anti-SSB antibody (n, %) | 3 (25.0) | 3 (6.3) | 0.053 |